安全分析放射性膀胱炎的长期使用非那吡啶。

文章的细节

引用

复制到剪贴板

SN, Britnell SR,布朗约

安全分析放射性膀胱炎的长期使用非那吡啶。

2019 4月22:1078155219842646 J杂志制药Pract。。doi: 10.1177 / 1078155219842646。

PubMed ID

31006341 (在PubMed

]

文摘

背景:非那吡啶是一种尿路刺激的镇痛表示短期治疗降低尿路。尽管缺乏证据扩展使用,通常是在不同时间用于支持照顾癌症患者放射性膀胱炎。本研究的目的是比较药品不良反应的发生率放射性膀胱炎患者接受长期非那吡啶(> 14天供应)相比,匹配比较器组。方法:回顾性队列研究相比,癌症患者和没有非那吡啶中不良事件曝光。包括患者接受放疗和至少有一个慢性药物2008年7月1日至2017年6月30日。非那吡啶组也得到了> 14天在研究期间非那吡啶的供应。患者匹配基于性别、年龄(+ / 5年),癌症诊断,缓和或治疗治疗意图。数据收集发生在基线,在假定接触的时间,通过研究结束的期限监控目的。结果:共有272名患者接受非那吡啶> 14天供应在研究期间。其中,90名患者包括和匹配同等数量的病人比较器组。 The included patients were similar between groups and were largely male with a diagnosis of prostate cancer. Most patients received between a 30- and 60-day supply of phenazopyridine. There were a total of 13 adverse drug reactions in the phenazopyridine group and 18 in the comparator group ( p = 0.32). No differences were identified between the phenazopyridine and comparator groups for the incidence of individual adverse drug reactions, emergency department visits, hospitalizations, or new diagnoses of hepatocellular or colorectal cancer. CONCLUSION: There was no difference in adverse drug reactions among patients receiving phenazopyridine for >14 days compared to a matched comparator group. The overall incidence of adverse events in both groups was low.

DrugBank数据引用了这篇文章

药物

非那吡啶